-+ 0.00%
-+ 0.00%
-+ 0.00%

StenoCare Q2 FY26 EBITDA rises 195% to DKK 56,000; net sales climb 33% vs Q1 FY26 to DKK 4 million

PUBT·08/20/2026 06:01:08
Listen to the news
StenoCare Q2 FY26 EBITDA rises 195% to DKK 56,000; net sales climb 33% vs Q1 FY26 to DKK 4 million
  • StenoCare reported Q2 net sales of DKK 4 million, up 33% versus Q1 2026 and more than doubled from Q2 2025.
  • EBITDA stayed positive at DKK 56,000, marking a fifth straight EBITDA-positive quarter.
  • Operating cash flow after financial items turned positive at DKK 1.56 million; cash at bank totaled DKK 1.74 million at June 30, 2026.
  • H1 net sales rose to DKK 7 million; H1 EBITDA improved to DKK 117,000 from a loss a year earlier.
  • CEO Thomas Skovlund Schnegelsberg cited Denmark-led growth while Germany lagged on prescribing and reimbursement changes; CannGros integration is complete, France preparations continue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: 20260819:BIT:9620:0) on August 20, 2026, and is solely responsible for the information contained therein.